|
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT methylation appears to convey a survival benefit in the setting of bevacizumab treatment for progressive GBM.
|
31756059 |
2020 |
|
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
In addition to its benefits for molecular subgrouping and copy number analysis of brain tumors, DNA-methylation based classification is a highly reliable tool for the assessment of MGMT promoter methylation status in glioblastoma patients.
|
31784096 |
2020 |
|
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The results confirm that the quantitative level of MGMT promoter methylation is a positive prognostic factor in newly diagnosed patients with GBM.
|
31422371 |
2020 |
|
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Some of these genetic alterations are currently believed to have clinical significance and are more related to secondary GBMs: TP53 mutations, detectable in the early stages of secondary GBM (found in 65%), isocitrate dehydrogenase 1/2 mutations (50% of secondary GBMs), and also O6-methylguanine-DNA methyltransferase promoter methylation (75% of secondary GBMs).
|
31550738 |
2020 |
|
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The CpG methylation status of the MGMT promoter strongly correlates with clinical outcome and, therefore, is used as prognostic marker during glioblastoma therapy.
|
31395346 |
2020 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we quantify baseline expression of MGMT and EGFR protein in newly diagnosed GBM samples using mass spectrometry.
|
31823165 |
2020 |
|
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
• ASL-PWI can aid to predict IDH and MGMT promoter methylation statuses in GBM.
|
31468161 |
2020 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Histological examination confirmed a wild-type (WT) IDH1/2, MGMT (DNA repair enzyme O6-methylguanine-DNA methyltransferase) methylated glioblastoma with a proliferative index focally as high as 20%.
|
31173153 |
2020 |
|
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter hypermethylation was detected in 38.7% of glioblastoma patients.
|
31701343 |
2020 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
LC-MS/MS plasma stability assays were conducted in mice to further explore the stability profile of TMZ@Calix <i>in vivo</i> The therapeutic efficacy of TMZ@Calix was compared with that of unbound TMZ in GBM cell lines and patient-derived primary cells with known O6-methylguanine-DNA methyltransferase (<i>MGMT</i>) expression status and <i>in vivo</i> in an intracranial U87 xenograft mouse model.
|
31213505 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The absence of systematic and clinically relevant changes in HRQOL and neurocognitive function combined with the survival benefit of lomustine-temozolomide versus temozolomide alone suggests that a long-term net clinical benefit exists for patients with newly diagnosed glioblastoma with methylation of the MGMT promoter and supports the use of lomustine-temozolomide as a treatment option for these patients.
|
31488360 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Methylation of the O(6)-Methylguanine-DNA methyltransferase (MGMT) promoter is predictive for treatment response in glioblastoma patients.
|
31167648 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We showed that ionizing radiation and temozolomide reduced the viability of cancer stem cells from GBM patients, as well as modified MGMT gene and miRNA-181d expression in cancer stem cells, suggesting that miRNA-181d interferes in the glioblastoma cancer stem cell response to treatment with temozolomide and ionizing radiation.
|
31226325 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The purpose of this study was to determine the effect of disulfiram (DSF), an aldehyde dehydrogenase inhibitor, on in vitro radiosensitivity of glioblastoma cells with different methylation status of O6-methylguanine-DNA methyltransferase (MGMT) promoter and the underlying mechanism of such effect.
|
30121967 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
GTR and MGMT promoter methylation are independent prognosticators for improved overall and progression-free survival in a homogeneous cohort of newly diagnosed patients with IDH wild-type glioblastoma.
|
29617848 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Temozolomide (TMZ) is the first-line chemotherapy drug for glioma, but whether TMZ should be withheld from patients with GBMs that lack O6-methylguanine-DNA methyltransferase (<i>MGMT</i>) promoter methylation is still under debate.
|
31611911 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Although the two classical molecular markers of glioblastoma including isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation are associated with overall survival rate of glioblastoma patients, they are not specific to the survival outliers.
|
31159876 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Surprisingly, integrative analyses demonstrated that O6-methylguanine-DNA methyltransferase methylation and isocitrate dehydrogenase mutation status were equally distributed among glioblastoma metabolic profiles.
|
30476237 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, because temozolomide did not cause phosphorylation of cPLA<sub>2</sub> in MGMT high-expressing glioblastoma T98G cells, phosphorylation of cPLA<sub>2</sub> may be caused by DNA alkylation of temozolomide.
|
31442413 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine whether there is a threshold for the TMZ-induced DNA damage response and exploring the factors regulating the switch between p53 dependent survival and death, the glioblastoma lines LN-229 (deficient in MGMT) and LN-229MGMT (stably transfected with MGMT) were exposed to different doses of TMZ. p53 protein expression and phosphorylation levels of p-p53ser15 and p-p53ser46 were determined by Western blotting.
|
30925722 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Studies examining the synergy between Dihydrotanshinone and Temozolomide against MGMT+ glioblastoma cells in vitro: Predicting interactions with the blood-brain barrier.
|
30399573 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Epigallocatechin Gallate Preferentially Inhibits O<sup>6</sup>-Methylguanine DNA-Methyltransferase Expression in Glioblastoma Cells Rather than in Nontumor Glial Cells.
|
30558449 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
O<sup>6</sup>-methylguanine-DNA-methyltransferase immunostaining intensity in glioblastoma.
|
29153917 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.
|
30189035 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival.
|
31058280 |
2019 |